Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/7585

Title: Standard versus alternating non-cross resistant chemotherapy in extensive disease small cell lung cancer: an EORTC study
Authors: Postmus, P.E.
Scagliotti, G.
Groen, H.J.M.
Gozzelino, F.
Burghouts, J.Th.W.
CURRAN, Desmond
Sahmoud, T.
Kirkpatrick, A.
Giaccone, G.
Splinter, T.A.W.
Issue Date: 1996
Publisher: Elsevier Science Ltd.
Citation: European journal of cancer, 32(9). p. 1498-1503
Abstract: Abstract Alternating chemotherapy for small cell lung cancer has been tested in several studies. Some have shown positive results that have not been confirmed in other studies. In all of the studies, however, the degree of non-cross-resistance in the regimens was questionable. The EORTC Lung Cancer Study Group developed two equipotent regimens: (i) standard (CDE)—cyclophosphamide, doxorubicin, etoposide; (ii) (VIMP)—vincristine, carboplatin, ifosfamide, mesna, both non-cross-resistance. These two combinations were alternated and compared with the standard chemotherapy regimen in a group of 143 patients with extensive small cell lung cancer. Median survival was 7.6 months in the standard arm and 8.7 in the alternating arm (P = 0.243). Median time to progression was 5.8 and 6.4 months, respectively (P = 0.166). Median response duration was 7.0 and 6.8 months (P = 0.221). The use of two alternating regimens with a proven degree of non-cross-resistance did not result in any improvement in survival in patients with extensive small cell lung cancer.
URI: http://hdl.handle.net/1942/7585
DOI: 10.1016/0959-8049(96)00145-1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.